Aflibercept (Zaltrap(®)) approved in Metastatic Colorectal Cancer.

This study showed an improved overall survival, with the combination of aflibercept and FOLFIRI versus FOLFIRI + placebo (13.5 months vs 12.06 months ; HR = 0,817, IC à 95 %, 0,714 à 0,935 ; p = 0,003 2). Adverse effects reported with aflibercept combined with FOLFIRI included the specific anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities. Aflibercept is the second anti-angiogenic agent after bevacizumab with a FDA and a EMEA approval for patients with metastatic colorectal cancer. PMID: 24047539 [PubMed - as supplied by publisher]
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research